Bio-Techne Corporation

NasdaqGS:TECH Stock Report

Market Cap: US$11.6b

Bio-Techne Future Growth

Future criteria checks 3/6

Bio-Techne is forecast to grow earnings and revenue by 21.2% and 8.8% per annum respectively. EPS is expected to grow by 20.3% per annum. Return on equity is forecast to be 13.8% in 3 years.

Key information

21.2%

Earnings growth rate

20.3%

EPS growth rate

Life Sciences earnings growth17.8%
Revenue growth rate8.8%
Future return on equity13.8%
Analyst coverage

Good

Last updated18 Dec 2024

Recent future growth updates

Recent updates

Why We're Not Concerned About Bio-Techne Corporation's (NASDAQ:TECH) Share Price

Dec 15
Why We're Not Concerned About Bio-Techne Corporation's (NASDAQ:TECH) Share Price

There May Be Reason For Hope In Bio-Techne's (NASDAQ:TECH) Disappointing Earnings

Nov 06
There May Be Reason For Hope In Bio-Techne's (NASDAQ:TECH) Disappointing Earnings

Is Bio-Techne (NASDAQ:TECH) A Risky Investment?

Sep 26
Is Bio-Techne (NASDAQ:TECH) A Risky Investment?

Why Bio-Techne Corporation (NASDAQ:TECH) Could Be Worth Watching

Sep 11
Why Bio-Techne Corporation (NASDAQ:TECH) Could Be Worth Watching

Bio-Techne Corporation's (NASDAQ:TECH) Price In Tune With Earnings

Aug 24
Bio-Techne Corporation's (NASDAQ:TECH) Price In Tune With Earnings

When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?

Jun 09
When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?

Bio-Techne Corporation's (NASDAQ:TECH) Shares Climb 33% But Its Business Is Yet to Catch Up

May 21
Bio-Techne Corporation's (NASDAQ:TECH) Shares Climb 33% But Its Business Is Yet to Catch Up

These 4 Measures Indicate That Bio-Techne (NASDAQ:TECH) Is Using Debt Reasonably Well

Apr 30
These 4 Measures Indicate That Bio-Techne (NASDAQ:TECH) Is Using Debt Reasonably Well

Bio-Techne Corporation (NASDAQ:TECH) Shares Could Be 32% Above Their Intrinsic Value Estimate

Apr 15
Bio-Techne Corporation (NASDAQ:TECH) Shares Could Be 32% Above Their Intrinsic Value Estimate

Bio-Techne: Secular Growth Opportunities Always Exhibit Financial Excellence

Apr 04

We Think Bio-Techne (NASDAQ:TECH) Can Stay On Top Of Its Debt

Jan 17
We Think Bio-Techne (NASDAQ:TECH) Can Stay On Top Of Its Debt

Bio-Techne Corporation (NASDAQ:TECH) Investors Are Less Pessimistic Than Expected

Dec 30
Bio-Techne Corporation (NASDAQ:TECH) Investors Are Less Pessimistic Than Expected

Bio-Techne releases new AVV viral titer assays

Oct 11

Bio-Techne to seek shareholder approval for 4- for-1 stock split

Sep 01

Earnings and Revenue Growth Forecasts

NasdaqGS:TECH - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
6/30/20271,4873257206058
6/30/20261,33726137142113
6/30/20251,22319829534714
9/30/20241,172151245303N/A
6/30/20241,159168236299N/A
3/31/20241,154203251307N/A
12/31/20231,145224225276N/A
9/30/20231,144247215258N/A
6/30/20231,137285216254N/A
3/31/20231,124271233274N/A
12/31/20221,120262252296N/A
9/30/20221,118292285333N/A
6/30/20221,106272280325N/A
3/31/20221,076225302345N/A
12/31/20211,030210308346N/A
9/30/2021985177295335N/A
6/30/2021931140308352N/A
3/31/2021848184225275N/A
12/31/2020799175201250N/A
9/30/2020760248179231N/A
6/30/2020739229153205N/A
3/31/2020755187170216N/A
12/31/2019745195165207N/A
9/30/201973493151183N/A
6/30/201971496156182N/A
3/31/2019703121171191N/A
12/31/201868296154173N/A
9/30/2018661128145165N/A
6/30/2018643126N/A170N/A
3/31/2018619112N/A156N/A
12/31/2017599114N/A160N/A
9/30/201757773N/A162N/A
6/30/201756376N/A144N/A
3/31/201754174N/A129N/A
12/31/201652882N/A141N/A
9/30/2016517101N/A138N/A
6/30/2016499104N/A144N/A
3/31/2016482105N/A145N/A
12/31/201546599N/A138N/A
9/30/2015456107N/A135N/A
6/30/2015452108N/A139N/A
3/31/2015427108N/A140N/A
12/31/2014408116N/A144N/A
9/30/2014380107N/A140N/A
6/30/2014358111N/A137N/A
3/31/2014345113N/A129N/A
12/31/2013330114N/A127N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: TECH's forecast earnings growth (21.2% per year) is above the savings rate (2.6%).

Earnings vs Market: TECH's earnings (21.2% per year) are forecast to grow faster than the US market (15.2% per year).

High Growth Earnings: TECH's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: TECH's revenue (8.8% per year) is forecast to grow slower than the US market (9.1% per year).

High Growth Revenue: TECH's revenue (8.8% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: TECH's Return on Equity is forecast to be low in 3 years time (13.8%).


Discover growth companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 02:03
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Bio-Techne Corporation is covered by 27 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
James Francis MainwaringAtlantic Equities LLP
Catherine Ramsey SchulteBaird